Canaccord Genuity Upgrades AngioDynamics (ANGO) to Buy
- Wall Street set for higher open as Omicron fears ease
- Pfizer (PFE) and BioNTech (BNTX) Say Early Data Shows Booster Protects Against Omicron Variant, Analyst Sees 'Best in Class Covid Franchise'
- Tesla (TSLA) PT Raised to Street High $1,580 at New Street Research on 'Multiple Strong Catalysts'
- Apple (AAPL) Cut iPhone Production 20% in September and October, Assembly Line Stopped for ‘Several Days’ for the First Time in Over 10 Years - Nikkei
- Visa (V) Launches Crypto Advisory Service, Presents Findings of New Survey
Canaccord Genuity analyst William Plovanic upgraded AngioDynamics (NASDAQ: ANGO) from Hold to Buy with a price target of $37.00 (from $28.00).
Shares of AngioDynamics closed at $25.76 yesterday.
You May Also Be Interested In
- CLSA Upgrades TechnoPro Holdings, Inc. (6028:JP) (TCCNY) to Buy (1)
- Bank of Queensland Ltd. (BOQ:AU) (BKQNY) PT Lowered to AUD9.38 at CLSA
- Barclays Upgrades Societe Generale SA (GLE:FP) (SCGLY) to Overweight
Create E-mail Alert Related CategoriesAnalyst PT Change, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!